欢迎来到《四川大学学报(医学版)》
杨弘鑫, 陈海宁, 张波, 等. 349例胃肠道间质瘤的预后影响因素分析[J]. 四川大学学报(医学版), 2013, 44(1): 155-158.
引用本文: 杨弘鑫, 陈海宁, 张波, 等. 349例胃肠道间质瘤的预后影响因素分析[J]. 四川大学学报(医学版), 2013, 44(1): 155-158.
YANG Hong-xin, CHEN Hai-ning, ZHANG Bo, et al. Prognostic Analysis of 349 Cases with Gastrointestinal Stromal Tumor[J]. Journal of Sichuan University (Medical Sciences), 2013, 44(1): 155-158.
Citation: YANG Hong-xin, CHEN Hai-ning, ZHANG Bo, et al. Prognostic Analysis of 349 Cases with Gastrointestinal Stromal Tumor[J]. Journal of Sichuan University (Medical Sciences), 2013, 44(1): 155-158.

349例胃肠道间质瘤的预后影响因素分析

Prognostic Analysis of 349 Cases with Gastrointestinal Stromal Tumor

  • 摘要: 目的 探讨影响胃肠道间质瘤(GIST)预后的因素。 方法 回顾性分析我院2006年1月至2011年9月收治的349例GIST患者的病例资料,并分析影响其预后的因素。 结果 335例患者行肿瘤完整切除术,14例行姑息切除术。288例(82.5%)获得随访,随访3~72月(中位时间33月),61例复发或转移,其中33例死亡。非条件logistic回归示:肿瘤部位(P=0.003,OR=1.412,95%CI:1.125~1.772)、危险度分级(P=0.011,OR=2.930,95%CI:1.278~6.716)、术后服用伊马替尼(P=0.009,OR=0.291,95%CI:0.115~0.734)是影响GIST患者术后复发或转移的独立因素。2006年至2008年期间128例患者Cox回归示:直径(P=0.034,OR=2.328,95%CI:1.065~5.089)、危险度分级(P=0.015,OR=3.031,95%CI:1.236~7.428)及术后服用伊马替尼(P=0.011,OR=0.259,95%CI:0.091~0.734)是影响术后3年生存率的独立因素。 结论 GIST缺乏特异性临床表现。肿瘤部位、直径、危险度分级均可影响预后。中高危患者术后口服伊马替尼可改善其预后。

     

    Abstract: Objective To investigate the prognostic factors of gastrointestinal stromal tumor(GIST). Methods Clinical data of 349 cases of GIST patients in our hospital between January 2006 and September 2011 were analyzed retrospectively and the prognostic factors were evaluated. Results 335 patients underwent R0 resection and 14 with palliative resection. With a follow-up of 288 (82.5%) patients (median:33 months, range 3-72 months), 61 patients with progressed were observed and 33 of them died. Unconditional logistic regression analysis showed that tumor location (P=0.003, OR=1.412, 95%CI:1.125-1.772), risk classification (P=0.011, OR=2.930, 95%CI:1.278-6.716) and use of imatinib treatment (P=0.009, OR=0.291, 95%CI:0.115-0.734) were independent factors for post-operative recurrence or metastasis. Survival analysis of 128 patients between January 2006 and December 2008, Cox regression analysis demonstrated diameter (P=0.034, OR=2.328, 95%CI:1.065-5.089), risk classification (P=0.015, OR=3.031, 95%CI:1.236-7.428) and use of imatinib treatment (P=0.011, OR=0.259, 95%CI:0.091-0.734) were independent prognosis factors. Conclusions No specific clinical manifestation was observed for GIST. Tumor location, diameter, risk classification and imatinib treatment could influence on prognosis. Radical resection combined with imatinib treatment could improve the prognosis.

     

© 2013 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回